What we're reading, July 27, 2016: UnitedHealth and Aetna are looking to join California's Medicaid program; the World Health Organization is considering removing transgender identity from list of mental disorders; and medical schools rethink how to treat addiction.
Next year, UnitedHealth and Aetna both plan to join California’s Medicaid program, Medi-Cal, in San Diego and Sacramento. The vast majority (80%) of people covered by Medi-Cal are in managed care plans, and with the program covering one-third of all Californians, the program is almost impossible to ignore, reported California Healthline. There are currently 2 insurers in Medi-Cal managed care and the last new insurer to join was Centene in 2013.
The World Health Organization (WHO) is considering removing transgender identity from the list of mental disorders. According to The New York Times, the change has already been approved by each committee that has considered it, and it is under review for the next edition of the WHO codebook. Removing transgender identity from the mental disorder list helps to reduce some of the stigma; however, the diagnosis won’t be removed entirely from the codebook, because having a code is sometimes the only way patients can receive care.
With the opioid epidemic in the United States, medical schools are retooling their curriculums to address the issue. NPR has highlighted the way some medical schools are changing how they teach about addiction. However, recruiting doctors to specialize in addiction medicine remains a challenge as the field has low reimbursement rates and patients can be difficult to handle.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More